Recurrent venous thromboembolism: A role for ABO blood group?

Thrombosis and Haemostasis

Volumn 110, Issue 6, 2013, Pages 1110-1111

  Dentali, Francesco ^a   Franchini, Massimo ^b  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b CARLO POMA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ANTICOAGULANT THERAPY; ARTICLE; BLOOD GROUP ABO SYSTEM; DEEP VEIN THROMBOSIS; FOLLOW UP; HEMOSTASIS; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); POSTTHROMBOSIS SYNDROME; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC); VEIN OCCLUSION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BLOOD GROUP ANTIGENS; FEMALE; HUMANS; MALE; VENOUS THROMBOEMBOLISM;

EID: 84888406378     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-09-0780     Document Type: Article

References (23)

1. White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107 (23 Suppl 1): I4-8.
2. Kyrle PA, Eichinger S. Clinical scores to predict recurrence risk of venous thromboembolism. Thromb Haemost 2012; 108: 1061-1064.
3. Thaler J, Ay C, Pabinger I. Venous thromboembolism in cancer patients-risk scores and recent randomised controlled trials. Thromb Haemost 2012; 108: 1042-1048.
4. Spyropoulos AC, McGinn T, Khorana AA. The use of weighted and scored risk assessment models for venous thromboembolism. Thromb Haemost 2012; 108: 1072-1076.
5. Ageno W, Dentali F, Donadini MP, Squizzato A. Optimal treatment duration of venous thrombosis. J Thromb Haemost 2013; 11 (Suppl 1): 151-160.
6. Angchaisuksiri P. Venous thromboembolism in Asia-an unrecognised and under-treated problem? Thromb Haemost 2011; 106: 585-590.
7. Wattanakit K, Lutsey PL, Bell EJ, et al. Association between cardiovascular disease risk factors and occurrence of venous thromboembolism. A timedependent analysis. Thromb Haemost 2012; 108: 508-515.
8. Bergrem A, Dahm AE, Jacobsen AF, et al. Differential haemostatic risk factors for pregnancy-related deep-vein thrombosis and pulmonary embolism: a population-based case-control study. Thromb Haemost 2012; 108: 1165-1171.
9. Franchini M, Favaloro EJ, Targher G, et al. ABO blood group, hypercoagulability, and cardiovascular and cancer risk. Crit Rev Clin Lab Sci 2012; 49: 137-149.
10. Franchini M, Liumbruno GM. ABO blood group: old dogma, new perspectives. Clin Chem Lab Med 2013; 51: 1545-1553.
11. Moeller A, Weippert-Kretschmer M, Prinz H, et al. Influence of ABO blood groups on primary hemostasis. Transfusion 2001; 41: 56-60.
12. Gill JC, Endres-Brooks J, Bauer PJ, et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69: 1691-1695.
13. Wu O, Bayoumi N, Vickers MA, et al. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost 2008; 6: 62-69.
14. Dentali F, Sironi AP, Ageno W, et al. Non-O blood type is the commonest genetic risk factor for VTE: results from a metaanalysis of the literature. Semin Thromb Hemost 2012; 38: 535-548.
15. Muellner SK, Haut ER, Streiff MB, et al. ABO blood group as a potential risk factor for venous thromboembolism in acutely injured patients. Thromb Haemost 2011; 105: 5-13.
16. Jang MJ, Yhim HY, Lee JO, et al. ABO blood types are associated with risk of idiopathic venous thromboembolism in the Korean population. A report from the Korean Venous Thromboembolism Working Party (KVTEWP). Thromb Haemost 2012; 107: 799-801.
17. Tufano A, Coppola A, Nardo A, et al. Non-O blood group as a risk factor for cerebral vein thrombosis. Thromb Haemost 2013; 110: 197-199.
18. Le Gal G, Kovacs MJ, Carrier M, et al. Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study. Thromb Haemost 2010; 104: 498-503.
19. Lecumberri R, Alfonso A, Jiménez D, et al.; and the RIETE investigators. Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism. Thromb Haemost 2013; 110: Epub ahead of print.
20. Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008; 179: 417-426.
21. Gandara E, Kovacs MJ, Kahn KR, et al. Non-OO blood type influences the risk of recurrent venous thromboembolism. A cohort study. Thromb Haemost 2013; 110: 1172-1179.
22. Dentali F, Di Minno MND, Turato S, et al. Role of ABO blood group and of thrombophilic abnormalities on the presence of residual vein obstruction after deep-vein thrombosis of the lower limbs. J Thromb Haemost 2013; 11 (Suppl. 2): 392 (abstract).
23. Cosmi B, Legnani C, Pengo V, et al.; PROLONG Investigators (on behalf of FCSA, Italian Federation of Anticoagulation Clinics). The influence of factor V Leiden and G20210A prothrombin mutation on the presence of residual vein obstruction after idiopathic deep-vein thrombosis of the lower limbs. Thromb Haemost 2013; 109: 510-516.